Cargando…

Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge

Intramuscular (IM) vaccination with formalin-inactivated respiratory syncytial virus (FI-RSV) failed in clinical trials due to vaccine-enhanced respiratory disease. To test the efficacy of skin vaccination against respiratory syncytial virus (RSV), we investigated the immunogenicity, efficacy, and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Soojin, Lee, Youri, Kwon, Young-Man, Lee, Young-Tae, Kim, Ki-Hye, Ko, Eun-Ju, Jung, Jae Hwan, Song, Manki, Graham, Barney, Prausnitz, Mark R., Kang, Sang-Moo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203256/
https://www.ncbi.nlm.nih.gov/pubmed/30365561
http://dx.doi.org/10.1371/journal.pone.0205071
_version_ 1783365846110830592
author Park, Soojin
Lee, Youri
Kwon, Young-Man
Lee, Young-Tae
Kim, Ki-Hye
Ko, Eun-Ju
Jung, Jae Hwan
Song, Manki
Graham, Barney
Prausnitz, Mark R.
Kang, Sang-Moo
author_facet Park, Soojin
Lee, Youri
Kwon, Young-Man
Lee, Young-Tae
Kim, Ki-Hye
Ko, Eun-Ju
Jung, Jae Hwan
Song, Manki
Graham, Barney
Prausnitz, Mark R.
Kang, Sang-Moo
author_sort Park, Soojin
collection PubMed
description Intramuscular (IM) vaccination with formalin-inactivated respiratory syncytial virus (FI-RSV) failed in clinical trials due to vaccine-enhanced respiratory disease. To test the efficacy of skin vaccination against respiratory syncytial virus (RSV), we investigated the immunogenicity, efficacy, and inflammatory disease after microneedle (MN) patch delivery of FI-RSV vaccine (FI-RSV MN) to the mouse skin with or without an adjuvant of monophosphoryl lipid A (MPL). Compared to IM vaccination, MN patch delivery of FI-RSV was more effective in clearing lung viral loads and preventing weight loss, and in diminishing inflammation, infiltrating immune cells, and T helper type 2 (Th2) CD4 T cell responses after RSV challenge. With MPL adjuvant, MN patch delivery of FI-RSV significantly increased the immunogenicity and efficacy as well as preventing RSV disease as evidenced by lung viral clearance and avoiding pulmonary histopathology. Improved efficacy and prevention of disease by FI-RSV MN with MPL were correlated with no sign of airway resistance, lower levels of Th2 cytokines and infiltrating innate inflammatory cells, and higher levels of Th1 T cell responses into the lung. This study suggests that MN patch delivery of RSV vaccines to the skin with MPL adjuvant would be a promising vaccination method.
format Online
Article
Text
id pubmed-6203256
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-62032562018-11-19 Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge Park, Soojin Lee, Youri Kwon, Young-Man Lee, Young-Tae Kim, Ki-Hye Ko, Eun-Ju Jung, Jae Hwan Song, Manki Graham, Barney Prausnitz, Mark R. Kang, Sang-Moo PLoS One Research Article Intramuscular (IM) vaccination with formalin-inactivated respiratory syncytial virus (FI-RSV) failed in clinical trials due to vaccine-enhanced respiratory disease. To test the efficacy of skin vaccination against respiratory syncytial virus (RSV), we investigated the immunogenicity, efficacy, and inflammatory disease after microneedle (MN) patch delivery of FI-RSV vaccine (FI-RSV MN) to the mouse skin with or without an adjuvant of monophosphoryl lipid A (MPL). Compared to IM vaccination, MN patch delivery of FI-RSV was more effective in clearing lung viral loads and preventing weight loss, and in diminishing inflammation, infiltrating immune cells, and T helper type 2 (Th2) CD4 T cell responses after RSV challenge. With MPL adjuvant, MN patch delivery of FI-RSV significantly increased the immunogenicity and efficacy as well as preventing RSV disease as evidenced by lung viral clearance and avoiding pulmonary histopathology. Improved efficacy and prevention of disease by FI-RSV MN with MPL were correlated with no sign of airway resistance, lower levels of Th2 cytokines and infiltrating innate inflammatory cells, and higher levels of Th1 T cell responses into the lung. This study suggests that MN patch delivery of RSV vaccines to the skin with MPL adjuvant would be a promising vaccination method. Public Library of Science 2018-10-26 /pmc/articles/PMC6203256/ /pubmed/30365561 http://dx.doi.org/10.1371/journal.pone.0205071 Text en © 2018 Park et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Park, Soojin
Lee, Youri
Kwon, Young-Man
Lee, Young-Tae
Kim, Ki-Hye
Ko, Eun-Ju
Jung, Jae Hwan
Song, Manki
Graham, Barney
Prausnitz, Mark R.
Kang, Sang-Moo
Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge
title Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge
title_full Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge
title_fullStr Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge
title_full_unstemmed Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge
title_short Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge
title_sort vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid a enhances the protective efficacy and diminishes inflammatory disease after challenge
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203256/
https://www.ncbi.nlm.nih.gov/pubmed/30365561
http://dx.doi.org/10.1371/journal.pone.0205071
work_keys_str_mv AT parksoojin vaccinationbymicroneedlepatchwithinactivatedrespiratorysyncytialvirusandmonophosphoryllipidaenhancestheprotectiveefficacyanddiminishesinflammatorydiseaseafterchallenge
AT leeyouri vaccinationbymicroneedlepatchwithinactivatedrespiratorysyncytialvirusandmonophosphoryllipidaenhancestheprotectiveefficacyanddiminishesinflammatorydiseaseafterchallenge
AT kwonyoungman vaccinationbymicroneedlepatchwithinactivatedrespiratorysyncytialvirusandmonophosphoryllipidaenhancestheprotectiveefficacyanddiminishesinflammatorydiseaseafterchallenge
AT leeyoungtae vaccinationbymicroneedlepatchwithinactivatedrespiratorysyncytialvirusandmonophosphoryllipidaenhancestheprotectiveefficacyanddiminishesinflammatorydiseaseafterchallenge
AT kimkihye vaccinationbymicroneedlepatchwithinactivatedrespiratorysyncytialvirusandmonophosphoryllipidaenhancestheprotectiveefficacyanddiminishesinflammatorydiseaseafterchallenge
AT koeunju vaccinationbymicroneedlepatchwithinactivatedrespiratorysyncytialvirusandmonophosphoryllipidaenhancestheprotectiveefficacyanddiminishesinflammatorydiseaseafterchallenge
AT jungjaehwan vaccinationbymicroneedlepatchwithinactivatedrespiratorysyncytialvirusandmonophosphoryllipidaenhancestheprotectiveefficacyanddiminishesinflammatorydiseaseafterchallenge
AT songmanki vaccinationbymicroneedlepatchwithinactivatedrespiratorysyncytialvirusandmonophosphoryllipidaenhancestheprotectiveefficacyanddiminishesinflammatorydiseaseafterchallenge
AT grahambarney vaccinationbymicroneedlepatchwithinactivatedrespiratorysyncytialvirusandmonophosphoryllipidaenhancestheprotectiveefficacyanddiminishesinflammatorydiseaseafterchallenge
AT prausnitzmarkr vaccinationbymicroneedlepatchwithinactivatedrespiratorysyncytialvirusandmonophosphoryllipidaenhancestheprotectiveefficacyanddiminishesinflammatorydiseaseafterchallenge
AT kangsangmoo vaccinationbymicroneedlepatchwithinactivatedrespiratorysyncytialvirusandmonophosphoryllipidaenhancestheprotectiveefficacyanddiminishesinflammatorydiseaseafterchallenge